Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2016

01.09.2016 | short review

Indolent lymphoma at ASH 2015: new treatment approaches

verfasst von: MD Thomas Nösslinger

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

At the last American society of hematology (ASH) meeting new genetic prognostic tools for follicular lymphoma (FL) were presented. Recent clinical data support the potential use of chemotherapy-free combinations in treatment-naïve FL, but potential additive toxicities have to be considered. In relapsed disease the bcl2 inhibitor venetoclax (ABT-199) is very promising in combination with chemo-immunotherapy. Furthermore the concept of CAR-T cell therapy seems to be appropriate in highly refractory disease.
In younger patients with mantle cell lymphoma (MCL) minimal residual disease (MRD) and positrone emission tomography (PET) negativity after induction therapy are highly predicitive for the outcome after autologous transplantation. Bortezomib consolidation/maintenance trials after autologous transplantation yield conflicting results. In relapsed MCL ibrutinib is significantly more effective and also less toxic than temsirolimus.
Literatur
1.
Zurück zum Zitat Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for folicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111–22. CrossRefPubMed Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for folicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111–22. CrossRefPubMed
2.
Zurück zum Zitat Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after R‑CHOP defines patients at high risk for death: an analysis from the national LymphoCare study. J Clin Oncol. 2015;10;33(23):2516–22. CrossRef Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after R‑CHOP defines patients at high risk for death: an analysis from the national LymphoCare study. J Clin Oncol. 2015;10;33(23):2516–22. CrossRef
3.
Zurück zum Zitat Jurinovic V, Kridel R, Staiger A, et al. A clinicogenetic risk model (m7-FLIPI) prospectively identifies one-half of patients with early disease progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2015;126(23):abstr 333, ASH Annual Meeting Abstracts. Jurinovic V, Kridel R, Staiger A, et al. A clinicogenetic risk model (m7-FLIPI) prospectively identifies one-half of patients with early disease progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2015;126(23):abstr 333, ASH Annual Meeting Abstracts.
4.
Zurück zum Zitat Fowler N, Nastoupil L, de Vos S. Ibrutinib plus rituximab in treatment-naïve patients with follicular lymphoma: results from a multicenter, phase 2 study. Blood. 2015;126(23):abstr 470, ASH Annual Meeting Abstracts. Fowler N, Nastoupil L, de Vos S. Ibrutinib plus rituximab in treatment-naïve patients with follicular lymphoma: results from a multicenter, phase 2 study. Blood. 2015;126(23):abstr 470, ASH Annual Meeting Abstracts.
5.
Zurück zum Zitat Ujjani C, Jung SH, Pitcher B, et al. Phase I study of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma (Alliance 051103). Blood. 2015;126(23):abstr 471, ASH Annual Meeting Abstracts. Ujjani C, Jung SH, Pitcher B, et al. Phase I study of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma (Alliance 051103). Blood. 2015;126(23):abstr 471, ASH Annual Meeting Abstracts.
6.
Zurück zum Zitat De Vos S, Swinnen L, Kozloff M, et al. A dose-escalation study of venetoclax (ABT-199/GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-hodgkin’s lymphoma. Blood. 2015;126(23):abstr 255, ASH Annual Meeting Abstracts. De Vos S, Swinnen L, Kozloff M, et al. A dose-escalation study of venetoclax (ABT-199/GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-hodgkin’s lymphoma. Blood. 2015;126(23):abstr 255, ASH Annual Meeting Abstracts.
7.
Zurück zum Zitat Cheson B, Chua N, Mayer J, et al. Primary results from the phase III GADOLIN study of obinutuzumab plus bendamustine versus bendamustine alone in rituximab-refractory indolent non-hodgkin lymphom. Hematol Oncol. 2015;33(167):abstr 123. Cheson B, Chua N, Mayer J, et al. Primary results from the phase III GADOLIN study of obinutuzumab plus bendamustine versus bendamustine alone in rituximab-refractory indolent non-hodgkin lymphom. Hematol Oncol. 2015;33(167):abstr 123.
8.
Zurück zum Zitat Fowler N, Nastoupil L, Pinto RM, et al. A phase I study of lenalidomide plus a next generation anti-CD20 antibody, obinutuzumab, in relapsed indolent lymphoma. Blood. 2015;126(23):abstr 2742, ASH Annual Meeting Abstracts. Fowler N, Nastoupil L, Pinto RM, et al. A phase I study of lenalidomide plus a next generation anti-CD20 antibody, obinutuzumab, in relapsed indolent lymphoma. Blood. 2015;126(23):abstr 2742, ASH Annual Meeting Abstracts.
9.
Zurück zum Zitat Schuster S, Svoboda J, Nasta SD, et al. Sustained remissions following chimeric antigenreceptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. Blood. 2015;126(23):abstr 183, ASH Annual Meeting Abstracts. Schuster S, Svoboda J, Nasta SD, et al. Sustained remissions following chimeric antigenreceptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. Blood. 2015;126(23):abstr 183, ASH Annual Meeting Abstracts.
10.
Zurück zum Zitat Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab maintenance versus wait and watch after four courses of R‑DHAP followed by autologous stem cell transplantation in previously untreated young patients with mantle cell lymphoma: first interim analysis of the phase III prospective lyma trial, a lysa study. Blood. 2014;124:abstr 146, ASH Annual Meeting Abstracts. Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab maintenance versus wait and watch after four courses of R‑DHAP followed by autologous stem cell transplantation in previously untreated young patients with mantle cell lymphoma: first interim analysis of the phase III prospective lyma trial, a lysa study. Blood. 2014;124:abstr 146, ASH Annual Meeting Abstracts.
11.
Zurück zum Zitat Le Gouill S, Bodet-Milin C, Bailly C, et al. Predictive power of FDG-PET parameters at diagnosis and after induction in patients with mantle cell lymphoma, interim results from the LyMa-PET project. Blood. 2015;126(23):abstr 335, ASH Annual Meeting Abstracts. Le Gouill S, Bodet-Milin C, Bailly C, et al. Predictive power of FDG-PET parameters at diagnosis and after induction in patients with mantle cell lymphoma, interim results from the LyMa-PET project. Blood. 2015;126(23):abstr 335, ASH Annual Meeting Abstracts.
12.
Zurück zum Zitat Callanan M, Delfau MH, Macintyre E, et al. Predictice power of early, sequential MRD monitoring in peripheral blood and bone marrow in patients with mantle cell lymphoma following autologous stem cell transplantation with or without rituximab maintenance; interim results from the LyMa-MRD project. Blood. 2015;126(23):abstr 338, ASH Annual Meeting Abstracts. Callanan M, Delfau MH, Macintyre E, et al. Predictice power of early, sequential MRD monitoring in peripheral blood and bone marrow in patients with mantle cell lymphoma following autologous stem cell transplantation with or without rituximab maintenance; interim results from the LyMa-MRD project. Blood. 2015;126(23):abstr 338, ASH Annual Meeting Abstracts.
13.
Zurück zum Zitat Kaplan L, Jung SH, Stock W, et al. Bortezomib maintenance (BM) versus consolidiation (BC) following aggressive immunochemotherapy and autologous stem cell transplantation for untreated mantle cell lymphoma: CALGB (Alliance) 50403. Blood. 2015;126(23):abstr 337, ASH Annual Meeting Abstract. Kaplan L, Jung SH, Stock W, et al. Bortezomib maintenance (BM) versus consolidiation (BC) following aggressive immunochemotherapy and autologous stem cell transplantation for untreated mantle cell lymphoma: CALGB (Alliance) 50403. Blood. 2015;126(23):abstr 337, ASH Annual Meeting Abstract.
14.
Zurück zum Zitat Doorduijn J, Minnema M, Kersten MJ, et al. Bortezomib maintenance therapy after induction with R‑CHOP, ARA-C and autologous stem cell transplantation in newly diagnosed MCL patients, results of a multicentre phase II HOVON study. Blood. 2015;126(23):abstr 339, ASH Annual Meeting Abstracts. Doorduijn J, Minnema M, Kersten MJ, et al. Bortezomib maintenance therapy after induction with R‑CHOP, ARA-C and autologous stem cell transplantation in newly diagnosed MCL patients, results of a multicentre phase II HOVON study. Blood. 2015;126(23):abstr 339, ASH Annual Meeting Abstracts.
15.
Zurück zum Zitat Rule S, Jurczak W, Jerkeman M, et al. Ibrutinib vs temsirolimus: results from a phase 3, international, randomized, open-label, multicentre study in patients with previously treated mantle cell lymphoma. Blood. 2015;126(23):abstr 469, ASH Annual Meeting Abstracts. Rule S, Jurczak W, Jerkeman M, et al. Ibrutinib vs temsirolimus: results from a phase 3, international, randomized, open-label, multicentre study in patients with previously treated mantle cell lymphoma. Blood. 2015;126(23):abstr 469, ASH Annual Meeting Abstracts.
16.
Zurück zum Zitat Treon S, Tripsas C, Meid K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372(15):1430–40. CrossRefPubMed Treon S, Tripsas C, Meid K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372(15):1430–40. CrossRefPubMed
17.
Zurück zum Zitat Dimopoulos M, Tedeschi A, Matous J, et al. Ibrutinib therapy in rituximab-refractory patients with Waldenström’s macroglobulinemia: initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATETM). Blood. 2015;126(23):abstr 274–5, ASH Annual Meeting Abstracts. Dimopoulos M, Tedeschi A, Matous J, et al. Ibrutinib therapy in rituximab-refractory patients with Waldenström’s macroglobulinemia: initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATETM). Blood. 2015;126(23):abstr 274–5, ASH Annual Meeting Abstracts.
18.
Zurück zum Zitat Kiesewetter B, Greil R, Willenbacher W, Neumeister P, Raderer M. AGMT MALT-2: a phase II study of rituximab plus lenalidomide in patients with extranodal marginal zone B‑cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). Blood. 2015;126(23):abstr 3973, ASH Annual Meeting Abstracts. Kiesewetter B, Greil R, Willenbacher W, Neumeister P, Raderer M. AGMT MALT-2: a phase II study of rituximab plus lenalidomide in patients with extranodal marginal zone B‑cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). Blood. 2015;126(23):abstr 3973, ASH Annual Meeting Abstracts.
Metadaten
Titel
Indolent lymphoma at ASH 2015: new treatment approaches
verfasst von
MD Thomas Nösslinger
Publikationsdatum
01.09.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0274-4